Stocks · News reference
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Under Armour Exec Says Pressure From Middle East Conflict-Related Disruption Has Extended Into H2 FY27
Legend Biotech Announces Multiple Abstracts Accepted for 2026 ASH Annual Meeting
Legend Biotech will present new clinical and real-world data for CARVYKTI and updates on its next-generation cell therapy programs at the 2026 American Society of Hematology (ASH) Annual Meeting.
Nike vs. Procter & Gamble: Which Consumer Stock Is a Better Buy for 2027?
The article compares Nike and Procter & Gamble as investment options for 2027. Nike trades at a premium valuation (32.2x forward P/E) despite slowing revenue growth, though it offers an attractive 4.19% dividend yield and is on track to become a Dividend King. Procter & Gamble offers more defensive positioning with essential household goods, a lower valuation (23.2x forward P/E), and is already a Dividend King with 70 consecutive years of dividend increases. The author recommends P&G over Nike, citing P&G's superior 2026 performance (+14.1% vs Nike's -38.6%) and more stable business model.
On Holding Stock Drops After Mbappé's Controversial Comment
On Holding AG (NYSE: ONON) shares are falling Tuesday as Chinese companies end their deals with Kylian Mbappé. Here's what you should know.
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Legend Biotech Corporation announced it will host an investor conference call to discuss its financial results for the third quarter of 2026.